Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors during the central anxious system, conolidine modulates alternate molecular targets. A Science Advances review found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://robertf753kmo4.blogscribble.com/profile